Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Autor:	Foley TM; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Payne SN; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Pasch CA; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Yueh AE; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Van De Hey DR; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Korkos DP; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Clipson L; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin., Maher ME; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Matkowskyj KA; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin.; William S Middleton Memorial Veterans Hospital, Madison, Wisconsin., Newton MA; Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin., Deming DA; Division of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin. ddeming@medicine.wisc.edu.; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.; William S Middleton Memorial Veterans Hospital, Madison, Wisconsin.
Jazyk:	angličtina
Zdroj:	Molecular cancer research : MCR [Mol Cancer Res] 2017 Feb 09; Vol. 15 (3), pp. 317-327. Date of Electronic Publication: 2017 Feb 09.
DOI:	10.1158/1541-7786.MCR-16-0256
Abstrakt:	Therapeutic targeting of the PI3K pathway is an active area of research in multiple cancer types, including breast and endometrial cancers. This pathway is commonly altered in cancer and plays an integral role in numerous vital cellular functions. Mutations in the PIK3CA gene, resulting in a constitutively active form of PI3K, often occur in colorectal cancer, though the population of patients who would benefit from targeting this pathway has yet to be identified. In human colorectal cancers, PIK3CA mutations most commonly occur concomitantly with loss of adenomatous polyposis coli (APC). Here, treatment strategies are investigated that target the PI3K pathway in colon cancers with mutations in APC and PIK3CA Colorectal cancer spheroids with Apc and Pik3ca mutations were generated and characterized confirming that these cultures represent the tumors from which they were derived. Pan and alpha isomer-specific PI3K inhibitors did not induce a significant treatment response, whereas the dual PI3K/mTOR inhibitors BEZ235 and LY3023414 induced a dramatic treatment response through decreased cellular proliferation and increased differentiation. The significant treatment responses were confirmed in mice with Apc and Pik3ca -mutant colon cancers as measured using endoscopy with a reduction in median lumen occlusion of 53% with BEZ235 and a 24% reduction with LY3023414 compared with an increase of 53% in controls ( P < 0.001 and P = 0.03, respectively). This response was also confirmed with 18 F-FDG microPET/CT imaging. Implications: Spheroid models and transgenic mice suggest that dual PI3K/mTOR inhibition is a potential treatment strategy for APC and PIK3CA -mutant colorectal cancers. Thus, further clinical studies of dual PI3K/mTOR inhibitors are warranted in colorectal cancers with these mutations. Mol Cancer Res; 15(3); 1-11. ©2016 AACR. (©2016 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu